NewAmsterdam Pharma Co N.V. (NAMS) Earnings
NewAmsterdam Pharma Co N.V.'s most recently reported earnings, recent earnings filings (8-K) and headline annual financials, sourced from SEC EDGAR.
Next earnings (estimated)
Around Nov 11, 2026
From past filing pattern
Get notified when NAMS reports →Last reported earnings
Aug 5, 2026
From the latest earnings 8-K
Revenue • FY2025
$22.5M
▼ 50.6%YoY
Diluted EPS • FY2025
-$1.72
▲ 32.8%YoY
Reported earnings dates are based on the latest 8-K (Item 2.02) filings. The next earnings date is an estimate projected from NAMS's historical reporting pattern, not a company-confirmed date.
Headline financials
| Period | Revenue | Net income | Gross profit | Dil. EPS | Free cash flow | Op. margin | Rev. growth |
|---|---|---|---|---|---|---|---|
| FY2025 | $22.5M | -$203.82M | — | -$1.72 | -$148.03M | -1002.9% | -50.6% |
| FY2024 | $45.56M | -$241.6M | — | -$2.56 | -$159.24M | -386.9% | +223.4% |
| FY2023 | $14.09M | -$176.94M | — | -$2.15 | -$141.24M | -1298.6% | -86.3% |
Recent earnings filings
| Filed | Form | Accession |
|---|---|---|
| Aug 5, 2026 | 8-K (2.02) | 0001193125-26-333827EDGAR |
| May 7, 2026 | 8-K (2.02) | 0001193125-26-210283EDGAR |
| Feb 18, 2026 | 8-K (2.02) | 0001193125-26-056020EDGAR |
| Jan 9, 2026 | 8-K (2.02) | 0001193125-26-008300EDGAR |
| Nov 5, 2025 | 8-K (2.02) | 0001193125-25-265800EDGAR |
| Aug 6, 2025 | 8-K (2.02) | 0000950170-25-103520EDGAR |
| May 8, 2025 | 8-K (2.02) | 0000950170-25-066410EDGAR |
| Feb 26, 2025 | 8-K (2.02) | 0000950170-25-027336EDGAR |
Never miss a NAMS filing.
Get an email when NAMS files its next 8-K, Form 4, 10-K or 10-Q with the SEC. Free, no account needed.
Free foreverNo account requiredOne-click unsubscribe
Data as of Nov 5, 2026Source: SEC EDGAR.